Feedback / Questions
ifebemtinib (IN10018) - InxMed
https://www.manilatimes.net/2025/06/01/tmt-newswire/pr-newswire/inxmed-announces-promising-phase-ibii-clinical-data-for-ifebemtinib-kras-g12c-inhibitor-in-kras-g12c-mutant-solid-tumors-at-asco-2025/2124756
Jun 1, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next